Growth Metrics

Pharming Group N.V (PHAR) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$12.0 million.

  • Pharming Group N.V's Net Income towards Common Stockholders rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
  • Latest data reveals that Pharming Group N.V reported Net Income towards Common Stockholders of -$12.0 million as of FY2024, which was down 283.16% from -$3.1 million recorded in FY2023.
  • Pharming Group N.V's Net Income towards Common Stockholders' 5-year high stood at $37.7 million during FY2020, with a 5-year trough of -$12.0 million in FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$3.1 million (2023), whereas its average is $2.5 million.
  • In the last 5 years, Pharming Group N.V's Net Income towards Common Stockholders surged by 418.42% in 2022 and then crashed by 283.16% in 2024.
  • Pharming Group N.V's Net Income towards Common Stockholders (Yearly) stood at $37.7 million in 2020, then slumped by 118.70% to -$7.1 million in 2021, then surged by 418.42% to $22.5 million in 2022, then crashed by 113.90% to -$3.1 million in 2023, then crashed by 283.16% to -$12.0 million in 2024.